Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Beigene Ltd ADR
(NQ:
BGNE
)
193.82
-1.81 (-0.93%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Beigene Ltd ADR
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
BeiGene Initiates First-in-Human Phase 1 Clinical Trial of Investigational TYK2 Inhibitor BGB-23339
November 22, 2021
From
BeiGene
Via
Business Wire
Week In Review: BeiGene Cleared To Stage $3 Billion IPO On Shanghai STAR Exchange
November 20, 2021
Beijing's BeiGene was approved to stage a $3 billion IPO on Shanghai’s STAR Exchange, the company's third listing. Previously, the company completed an $182 million IPO on the NASDAQ in 2016 and a $900...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
BeiGene and NewBridge Pharmaceuticals Announce Approval in Saudi Arabia of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma
November 14, 2021
From
BeiGene
Via
Business Wire
Why BeiGene Shares Are Rising
September 17, 2021
Beigene Ltd (NASDAQ: BGNE) shares are trading higher by 3.8% at $400 after the company announced it received a positive CHMP opinion for BRUKINSA for the treatment of adults...
Via
Benzinga
Week In Review: Two China Affiliated Biopharmas Raise $585 Million In IPOs
November 06, 2021
LianBio raised $325 million in its Nasdaq IPO at a market capitalization of $1.9 billion to support its drug in-licensings for China. Beijing Clover Biopharma also completed a $260 million IPO in Hong...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
BeiGene Reports Third Quarter 2021 Financial Results
November 04, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Present Clinical Data on BRUKINSA in Chronic Lymphocytic Leukemia at the 63rd ASH Annual Meeting
November 04, 2021
From
BeiGene
Via
Business Wire
Here's My Top Value Stock To Buy Right Now
November 01, 2021
EXEL is working on further expanding cabozantinib’s label. It is currently evaluating the drug as a single agent and in combination with immune checkpoint inhibitors across various indications.
Via
Talk Markets
Wednesday Market Coverage
October 20, 2021
Today gold rose again despite the active market for bitcoin and the lower Chinese demand for mine products like iron and coal.
Via
Talk Markets
BeiGene and Nanolek Announce Approval in Russia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma
October 20, 2021
From
BeiGene
Via
Business Wire
Week In Review: Hansoh Signs $456 Million Deal For siRNA Products
October 16, 2021
Hansoh Pharma of Shanghai announced a $456 million agreement to develop siRNA products in Greater China from South Korea's OliX Pharma. Hansoh will make an upfront payment of $6.5 million and up to...
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021
October 12, 2021
Upgrades For Callaway Golf Co (NYSE:ELY), Compass ...
Via
Benzinga
BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma in Australia
October 10, 2021
From
BeiGene
Via
Business Wire
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
October 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)...
Via
Benzinga
Exposures
Product Safety
BeiGene Announces First Regulatory Approval in Australia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Waldenström’s Macroglobulinemia
October 07, 2021
From
BeiGene
Via
Business Wire
This Potential Indication Could Be a Winner for Novartis
September 29, 2021
The U.S. Food and Drug Administration accepted Novartis' filing for tislelizumab to treat esophageal cancer.
Via
The Motley Fool
Exposures
Product Safety
Notable Beigene Insider Trades $3.11 Million In Company Stock
September 23, 2021
Jane Huang, Cmo And Hematology at Beigene (NASDAQ:BGNE), made a large buy and sell of company shares on September 20, according to a new SEC filing. What Happened: A Form 4 filing...
Via
Benzinga
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
BeiGene Announces Inclusion in FTSE Russell Indices
September 20, 2021
From
BeiGene, Ltd.
Via
Business Wire
48 Biggest Movers From Friday
September 20, 2021
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by...
Via
Benzinga
Why BeiGene's Shares Jumped on Friday
September 17, 2021
The Chinese pharmaceutical company is racking up approvals for its lead oncology drug, Brukinsa.
Via
The Motley Fool
Beigene Insider Trades $33.79 Million In Company Stock
September 17, 2021
John Oyler, Chief Executive Officer at Beigene (NASDAQ:BGNE), made a large insider sell on September 15, according to a new SEC filing. What Happened: A Form 4 filing from the U....
Via
Benzinga
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
12 Health Care Stocks Moving In Friday's Pre-Market Session
September 17, 2021
Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) stock moved upwards by 53.98% to $3.48 during Friday's pre-market session. The company's market cap stands at $147.6...
Via
Benzinga
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia
September 17, 2021
From
BeiGene
Via
Business Wire
15 Stocks Moving in Friday's Pre-Market Session
September 17, 2021
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) rose 42% to $3.21 in pre-market trading. AbCellera Biologics Inc. (NASDAQ: ABCL) rose 18% to $23.35 in pre-market trading....
Via
Benzinga
Zymeworks' Zanidatamab Aces Mid-Stage Esophageal Cancer Trial
September 16, 2021
At the European Society of Medical Oncology Congress 2021 (ESMO21), Zymeworks Inc (NYSE: ZYME) presented encouraging early data on its HER2‑targeted bispecific antibody. Twenty-...
Via
Benzinga
Notable Beigene Insider Makes $4.62 Million Sale
September 16, 2021
Jane Huang, Cmo And Hematology at Beigene (NASDAQ:BGNE), made a large insider sell on September 13, according to a new SEC filing. What Happened: A Form 4 filing from the U.S....
Via
Benzinga
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
September 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC)...
Via
Benzinga
Leap Therapeutics Stock Is Moving Higher On Updated DKN-01 Combo Trial Data In Gastric Cancer
September 16, 2021
Leap Therapeutics Inc (NASDAQ: LPTX) announced updated data from the first-line cohort of the DisTinGuish Phase 2a trial evaluating DKN-01 combined with ...
Via
Benzinga
BeiGene's Brukinsa Scores FDA Approval For Marginal Zone Lymphoma
September 15, 2021
The FDA has granted accelerated approval to BeiGene Ltd's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for relapsed or refractory (R/R) marginal zone lymphoma (...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
September 15, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC)...
Via
Benzinga
Exposures
COVID-19
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.